COMMUNIQUÉS West-GlobeNewswire

Helius Medical Technologies Announces Reverse Stock Split
30/04/2025
NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference
30/04/2025
MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced [...]
Senti Bio to Present at the Citizens JMP Life Sciences Conference
30/04/2025
Live video webcast presentation on Thursday, May 8 th at 1:00 PM ET Presentation will highlight the recently announced positive preliminary clinical results of lead program, SENTI-202, in the treatment of patients with [...]
Notice of Annual General Meeting 2025
30/04/2025
Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST). The notice and proposed [...]
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
30/04/2025
Recognized for Advancing Global Wound Care Through Innovation and Efficacy AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 [...]
DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies
30/04/2025
Reconnu pour ses avancées dans le domaine des soins des plaies à l’échelle mondiale grâce à son caractère innovant et à son efficacité AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, le produit phare de DEBx [...]
Mountainside Joins Northwell Direct Network to Offer Best-in-Class Addiction Treatment
30/04/2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Mountainside Treatment Center is pleased to be named an in-network provider with Northwell Direct, owned by Northwell Health, New York State’s largest healthcare provider and [...]
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
30/04/2025
This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can reduce the risk of cancer recurrence and spread ATHENS, Greece and LOS ANGELES, April 30, [...]
Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia
30/04/2025
Singapore , April 30, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) , today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider [...]
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
30/04/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 30, 2025 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2025. Business highlights Q1 2025 QUVIVIQ™ ( [...]
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
30/04/2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comparable growth rate ( [...]
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
30/04/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO
30/04/2025
Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO New recruits expand senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT [...]
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
30/04/2025
Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home 1-4 Phesgo label expansion [...]
Nicox : Résultats financiers de l’année 2024
30/04/2025
Communiqué de presse Nicox : Résultats financiers de l’année 2024 Chiffre d’affaires de Nicox SA de 7,9 millions d’euros pour l’année 2024 Produits exceptionnels de 13,7 millions d’euros suite à la cession du flux futur [...]
Nicox Provides Full Year 2024 Financial Results
30/04/2025
Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus [...]
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025
30/04/2025
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard Au congrès annuel de l’AACR 2025 Une nouvelle signature d’expression génique pour prédire la réponse clinique [...]
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
30/04/2025
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response to immune [...]
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
30/04/2025
L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement [...]

Pages